SG76631A1 - Antitumor activity strengthening method of crude drugs composition containing crude drug strengthening antitumor activity evaluating method of antitumor effectiveness by crude drug treatment and evaluating method of antitumor effectiveness of crude drug - Google Patents

Antitumor activity strengthening method of crude drugs composition containing crude drug strengthening antitumor activity evaluating method of antitumor effectiveness by crude drug treatment and evaluating method of antitumor effectiveness of crude drug

Info

Publication number
SG76631A1
SG76631A1 SG1999004406A SG1999004406A SG76631A1 SG 76631 A1 SG76631 A1 SG 76631A1 SG 1999004406 A SG1999004406 A SG 1999004406A SG 1999004406 A SG1999004406 A SG 1999004406A SG 76631 A1 SG76631 A1 SG 76631A1
Authority
SG
Singapore
Prior art keywords
crude drug
antitumor
strengthening
effectiveness
evaluating method
Prior art date
Application number
SG1999004406A
Other languages
English (en)
Inventor
Kozo Niwa
Original Assignee
Kozo Niwa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kozo Niwa filed Critical Kozo Niwa
Publication of SG76631A1 publication Critical patent/SG76631A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
SG1999004406A 1998-09-17 1999-08-31 Antitumor activity strengthening method of crude drugs composition containing crude drug strengthening antitumor activity evaluating method of antitumor effectiveness by crude drug treatment and evaluating method of antitumor effectiveness of crude drug SG76631A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26375398 1998-09-17
JP10323374A JP2000159682A (ja) 1998-09-17 1998-11-13 生薬の抗腫瘍活性強化方法、抗腫瘍活性強化生薬含有組成物、生薬処理の抗腫瘍有効性評価方法、および生薬の抗腫瘍有効性評価方法

Publications (1)

Publication Number Publication Date
SG76631A1 true SG76631A1 (en) 2000-11-21

Family

ID=26546176

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1999004406A SG76631A1 (en) 1998-09-17 1999-08-31 Antitumor activity strengthening method of crude drugs composition containing crude drug strengthening antitumor activity evaluating method of antitumor effectiveness by crude drug treatment and evaluating method of antitumor effectiveness of crude drug

Country Status (19)

Country Link
JP (1) JP2000159682A (nl)
KR (1) KR20000023206A (nl)
CN (1) CN1255376A (nl)
AU (1) AU4486299A (nl)
BE (1) BE1012725A5 (nl)
CA (1) CA2282234A1 (nl)
DE (1) DE19944695A1 (nl)
DK (1) DK199901235A (nl)
ES (1) ES2155802B1 (nl)
FR (2) FR2783426A1 (nl)
GB (2) GB9920710D0 (nl)
ID (1) ID23150A (nl)
IL (1) IL131722A0 (nl)
IS (1) IS5183A (nl)
IT (1) IT1307267B1 (nl)
NL (2) NL1013049C2 (nl)
NO (1) NO994463L (nl)
SE (2) SE9903307L (nl)
SG (1) SG76631A1 (nl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354355T1 (de) * 2001-04-27 2007-03-15 Ajinomoto Kk Eine dispersion aus beta-glukan enthaltenden hochfeinen partikel, ein entsprechender herstellungsprozess und die verwendung der dispersion
CN1320121C (zh) * 2001-05-07 2007-06-06 拜奥哈步株式会社 制备蘑菇乳酸发酵溶液的方法及由此制备的蘑菇乳酸发酵溶液
JP4499979B2 (ja) * 2001-05-21 2010-07-14 コンビ株式会社 病原菌感染抑制用組成物
JP4561098B2 (ja) * 2001-06-01 2010-10-13 味の素株式会社 糖尿病用薬剤
JP4681801B2 (ja) * 2002-05-15 2011-05-11 ビーエイチエヌ株式会社 血管新生阻害剤およびその製造方法
KR100971599B1 (ko) 2002-05-15 2010-07-20 비에이취엔 가부시끼가이샤 혈관 관련 질환의 예방 또는 치료를 위한 조성물
JP4826696B2 (ja) * 2003-04-07 2011-11-30 ビーエイチエヌ株式会社 血管新生阻害剤
JP2005089417A (ja) * 2003-09-19 2005-04-07 Noevir Co Ltd 糖尿病予防・治療用組成物
JP4587441B2 (ja) * 2004-02-12 2010-11-24 株式会社クレハ 新規な糖尿病治療剤および食品
JP5034071B2 (ja) * 2004-09-17 2012-09-26 株式会社Ｓ・Ｓ・Ｉ 乳癌を抑制するカワリハラタケ抽出物
JP2006273835A (ja) * 2005-03-04 2006-10-12 Michishi Tani 悪性腫瘍治療剤及びそれを含む飲食品
US20120128856A1 (en) * 2009-07-31 2012-05-24 Ming East-West, Llc Maitake mushroom coffee
WO2011081024A1 (ja) * 2009-12-29 2011-07-07 株式会社富士見養蜂園 旨味食品及びその製造方法
CN106333969A (zh) * 2016-08-30 2017-01-18 青海民族大学 圆孢蘑菇抑制hdac1酶有效部位及制法和应用
CN106309511A (zh) * 2016-08-30 2017-01-11 青海民族大学 圆孢蘑菇抑制cdc25酶有效部位及制法和应用
WO2019104579A1 (en) * 2017-11-30 2019-06-06 SHIEH, Darbin Method for predicting and modulating susceptibility of cancer cell to programmed cell death
KR102646421B1 (ko) * 2020-12-16 2024-03-12 대한민국 잎새버섯 생리활성성분 및 영양성분의 함량을 증가시키는 방법
KR102602787B1 (ko) * 2020-12-16 2023-11-17 대한민국 꽃송이버섯 생리활성성분 및 영양성분의 함량을 증가시키는 방법
KR102584680B1 (ko) * 2020-12-17 2023-10-06 대한민국 생리활성 및 영양성분이 증가된 표고버섯차 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276413A (en) * 1975-12-18 1977-06-27 Kureha Chem Ind Co Ltd Production of oncostatic substances
US4177108A (en) * 1977-03-02 1979-12-04 Tetsuro Ikekawa Process for producing emitanin
DE2842691A1 (de) * 1978-09-30 1980-04-10 Karl Dr Med Theurer Energetische anregung biologischer arzneimittel
JPS57206618A (en) * 1981-06-12 1982-12-18 Noda Shiyokukin Kogyo Kk Preparation of antitumor substance
JPH02203765A (ja) * 1989-02-02 1990-08-13 Nippon Beet Sugar Mfg Co Ltd 抗腫瘍機能を有する食品及びその製造法
JP3357383B2 (ja) * 1991-08-14 2002-12-16 昌宏 黒田 低分子化植物性組成物
JP2955126B2 (ja) * 1992-06-22 1999-10-04 笑代 丹羽 医薬用油性製剤、食品用油性製剤およびそれらの製造方法
US6015913A (en) * 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans

Also Published As

Publication number Publication date
NL1013049A1 (nl) 2000-03-21
NO994463D0 (no) 1999-09-15
KR20000023206A (ko) 2000-04-25
NL1013049C2 (nl) 2002-01-11
FR2783426A1 (fr) 2000-03-24
ES2155802A1 (es) 2001-05-16
ITTO990784A1 (it) 2001-03-14
DE19944695A1 (de) 2000-03-30
IL131722A0 (en) 2001-03-19
BE1012725A5 (fr) 2001-02-06
CA2282234A1 (en) 2000-03-17
GB2341800A (en) 2000-03-29
SE0100195D0 (sv) 2001-01-24
GB9920710D0 (en) 1999-11-03
SE0100195L (sv) 2001-01-24
CN1255376A (zh) 2000-06-07
ES2155802B1 (es) 2001-12-01
JP2000159682A (ja) 2000-06-13
NO994463L (no) 2000-03-20
NL1019705A1 (nl) 2002-01-29
IT1307267B1 (it) 2001-10-30
DK199901235A (da) 2000-03-18
IS5183A (is) 2000-03-17
AU4486299A (en) 2000-03-30
ITTO990784A0 (it) 1999-09-14
NL1019705C2 (nl) 2002-03-26
ID23150A (id) 2000-03-23
FR2788697A1 (fr) 2000-07-28
SE9903307D0 (sv) 1999-09-16
SE9903307L (sv) 2000-03-18
GB9921387D0 (en) 1999-11-10

Similar Documents

Publication Publication Date Title
SG76631A1 (en) Antitumor activity strengthening method of crude drugs composition containing crude drug strengthening antitumor activity evaluating method of antitumor effectiveness by crude drug treatment and evaluating method of antitumor effectiveness of crude drug
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
PL341592A1 (en) Method of administering human aspb28 insulin
HUP9601698A2 (hu) Cukorbetegség elleni (antidiabetikus) hatású gyógyászati készítmény
HUP0103839A3 (en) Use of certain drugs for treating nerve root injury
EP1067906A4 (en) MAXIMIZE THE EFFECTIVENESS OF SUBSTANCES WHICH ARE IMPROVED TO IMPROVE HEALTH AND WELL-BEING
IL132388A0 (en) Kappa-opioid agonist compounds pharmaceutical compositions and method of prevention and treatment of pruritus therewith
PL340994A1 (en) Method of administering therapeutic substances by inhalation and inhaler therefor
GB9812056D0 (en) Pharmaceutical composition for treatment of ibd and rbd
PL321003A1 (en) Derivatives of piperasine, drugs containing them, their application and methods of obtaining them
EP1003523A4 (en) COMPILATION AND TREATMENT METHOD OF LIVER TUMORS
ZA984268B (en) Method and composition for administering taxanes orally to human patients
ZA9670B (en) Composition and methods for transdermal delivery of acid-lability drugs
HUP9800970A3 (en) Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0201966A2 (en) Methods of treatment and drug screening methods
HUP9802716A3 (en) Pharmaceutical composition of analgesic activity
PL338140A1 (en) Method of treating diebetes by means of derivatives of thiazolydinone, of insulin secretion stimulating agent and of alpha-glucosidase inhibitor
GB2343844B (en) Composition and method for treatment of hypertrophic skin accumlations and their prevention
IL128966A (en) Pharmaceutical composition containing sulodexide for treatment of diabetic retinopathy
EP1009433A4 (en) THERAPEUTIC COMPOSITION AND TREATMENT METHOD
IL133908A0 (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (ssri)
ZA995910B (en) Antitumor activity strengthening method of crude drugs, and composition containing crude drug strengthening antitumor activity.
HUP0203676A3 (en) Pharmaceutical composition and method for treatment of diabetes
HU9802142D0 (en) Use of na+/h+ -ion-exchange inhibitors for producing pharmaceutical compositions for treating and profilacting diseases of the central nerve system